Product image of Iqirvo (Elafibranor) supplied by GNH India

Iqirvo

Active Ingredient:
Elafibranor
Origin:
EU

Iqirvo (Elafibranor)

Elafibranor, the active ingredient in Iqirvo, is a dual PPAR‑α/δ agonist presented as an oral tablet for oral use. It is being studied for its potential to improve liver inflammation and metabolic parameters in patients with non‑alcoholic steatohepatitis and related metabolic disorders.

GNH India supplies Iqirvo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ipsen Pharma

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Iqirvo targets metabolic liver disease pathways, particularly those involved in non‑alcoholic steatohepatitis (NASH) and related conditions.

  • Non‑alcoholic steatohepatitis (NASH): may help reduce hepatic inflammation and fibrosis.
  • Dyslipidaemia: may improve serum lipid concentrations.
  • Metabolic syndrome: may influence insulin sensitivity and glucose metabolism.

How It Works

  • Elafibranor activates peroxisome proliferator‑activated receptors α and δ, leading to modulation of genes involved in fatty‑acid oxidation, lipid transport, inflammation, and fibrogenesis. This dual activation promotes a shift toward improved lipid metabolism and reduced inflammatory signaling in hepatic and peripheral tissues.

Side Effects

Common Side Effects

  • Headache: mild to moderate intensity.
  • Nausea: occasional, often transient.
  • Abdominal pain: mild discomfort in the upper abdomen.
  • Diarrhoea: loose stools occurring intermittently.
  • Increased serum creatinine: mild elevation observed in some patients.

Serious or Rare Side Effects

  • Elevated liver enzymes: significant rise in ALT/AST levels.
  • Gallbladder disease: occurrence of cholelithiasis or cholecystitis.
  • Pancreatitis: acute inflammation of the pancreas.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Cardiovascular events: rare cases of myocardial infarction reported.

Precautions & Warnings

Before initiating therapy, consider patient history and concurrent conditions.

  • Liver function monitoring: assess baseline enzymes and repeat periodically.
  • Renal function assessment: evaluate serum creatinine and eGFR.
  • Concomitant lipid‑lowering therapy: adjust doses if needed.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Elafibranor may interact with several drug classes; careful review is advised.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors: may increase elafibranor exposure.
  • High‑dose statins: risk of myopathy may be heightened.
  • Anticoagulants: potential for increased bleeding risk.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors: monitor for adverse effects.
  • Antidiabetic agents: possible enhancement of glucose‑lowering effect.
  • Bile‑acid sequestrants: may reduce absorption of elafibranor.

Frequently Asked Questions

Iqirvo (elafibranor) is being investigated for the treatment of non‑alcoholic steatohepatitis (NASH) and other metabolic liver conditions, where it may help reduce liver inflammation and fibrosis.

Elafibranor activates peroxisome proliferator‑activated receptors α and δ, which regulate genes involved in fatty‑acid oxidation, lipid transport, inflammation, and fibrogenesis, thereby influencing metabolic and inflammatory pathways in the liver.

The prescribed dose of Iqirvo is determined by the treating physician based on the patient’s clinical condition, laboratory results, and therapeutic goals. Dosage details are provided in the prescribing information.

Safety of Iqirvo in pregnancy or while breastfeeding has not been established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and only under medical supervision.

To order Iqirvo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Iqirvo belongs to the dual PPAR‑α/δ agonist class, which differs from other NASH therapies such as FXR agonists or GLP‑1 receptor agonists. Its mechanism focuses on modulating lipid metabolism and inflammation, offering an alternative therapeutic pathway.

Iqirvo tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect the product from moisture and direct sunlight to maintain stability.

Iqirvo is taken orally as a tablet, usually with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water.

Serious risks include significant elevations in liver enzymes, gallbladder disease, pancreatitis, severe allergic reactions, and rare cardiovascular events. Patients should be monitored regularly for these potential complications.

Iqirvo should be avoided in patients with known hypersensitivity to elafibranor or any excipients, those with severe liver impairment, and individuals for whom the risk–benefit profile is unfavorable, as determined by a healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Elafibranor

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT